Alnylam

Press Releases

Aug 14,2019
Summary ToggleAlnylam to Report New Clinical Results for Givosiran at the 2019 International Congress on Porphyrins and Porphyrias
PDF Version
Aug 13,2019
Summary ToggleAlnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
PDF Version
Aug 06,2019
Summary ToggleAlnylam Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Period Activity
PDF Version
Aug 05,2019
Summary ToggleAlnylam Announces U.S. Food and Drug Administration (FDA) Granted Priority Review of the Givosiran New Drug Application (NDA) for the Treatment of Acute Hepatic Porphyria
PDF Version
Jul 30,2019
Summary ToggleAlnylam Pharmaceuticals and GENESIS Pharma Partner to Commercialize ONPATTRO® (patisiran) in South East Europe
PDF Version
Jul 23,2019
Summary ToggleAlnylam to Webcast Conference Call Discussing Second Quarter 2019 Financial Results
PDF Version
Jul 23,2019
Summary ToggleAlnylam Launches ONPATTRO® (patisiran) for the Treatment of Polyneuropathy in hATTR Amyloidosis, the First-Ever RNAi Therapeutic Approved in Canada
PDF Version
Jul 16,2019
Summary ToggleAlnylam and 23andMe Collaborate on +MyFamily Program to Increase Awareness of TTR-Related Hereditary Amyloidosis
PDF Version
Jul 11,2019
Summary ToggleAlnylam Pharmaceuticals Announces Transition of Chief Financial Officer
PDF Version
Jul 09,2019
Summary ToggleFirst-in-class ‘gene-silencing’ therapy approved for NHS use in England to treat hereditary form of amyloidosis
PDF Version
Jul 01,2019
Summary ToggleAlnylam Submits Marketing Authorization Application to the European Medicines Agency for Givosiran for the Treatment of Acute Hepatic Porphyria
PDF Version
Jun 24,2019
Summary ToggleAlnylam Presents New ONPATTRO® (patisiran) Results at the 2019 Peripheral Nerve Society Annual Meeting
PDF Version
Jun 21,2019
Summary ToggleAlnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery
PDF Version
Jun 18,2019
Summary ToggleAlnylam Announces Approval in Japan of ONPATTRO® for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
PDF Version
Jun 17,2019
Summary ToggleAlnylam Completes Enrollment for ILLUMINATE-A Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
PDF Version
Jun 13,2019
Summary ToggleAlnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN)
PDF Version
Jun 05,2019
Summary ToggleAlnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria
PDF Version
May 31,2019
Summary ToggleAlnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
PDF Version
May 30,2019
Summary ToggleAlnylam to Webcast Presentations at Upcoming June Investor Conferences
PDF Version
May 29,2019
Summary ToggleAlnylam Announces New Leadership Appointments
PDF Version
Displaying 1 - 20 of 1034 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More